The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Will top 20p a share TODAY IMHO!!!!!!!!!!!!! Listen to this!!!!:-
https://www.proactiveinvestors.co.uk/companies/news/1046802/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-1046802.html
holy *****!!!!
"astra have 460 active cance trials with 140,000 patients involved.".
halo effect.... knock on impact. pipeline of 11 other possible customers, 6 are "household" names!!!!!!!>>
https://www.proactiveinvestors.co.uk/companies/news/1046802/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-1046802.html
Parsortix has FDA approval for medical use in the USA for Breast cancer. There is a massive world wide market for this alone. Massive.
Even more massive IMHO it can be used for ***ANY cancer during a cancer drug trial***. There is £ millions to be made from Parsortix being used during drug trials. The RNS of 4th Jan IS THE MOST SIGNIFICANT ANNOUNEMENT AGL HAVE MADE EVER IMHO. It shows with the dual CtDNA and CTC analysis a cancer that has matastacised can be MONITORED to find out HOW THE NEW DRUG IS PERFORMING !!!!!!!!! Before. DURING and AFTER treatment!!!!
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
I expect, apart from the cash, the publicity and the downstream contract potential of this, one of the advantages is that it facilitates FDA approval.
Sp peaked around 13:45 @ 17p bid After the FIRST Astrazeneca contract on 24th April.....
Going up again after a little breather
Hello.
Ask 16p now.
Nobody wanted it until they wanted it
News flow has started
All time low, 99% down and now only limited shares available on the ask
After the FIRST Astrazeneca contract on 24th April.....
USA interest presumably..........
For every assay that Angle develop:-
- the assay development fees will be low ($250k - $750k depending on complexity)
- following the assay development there should be multiple phase 1/2 trial contracts, with multiple pharma, with higher value ($1m-$3m depending on number of patients / tests per patient)
- a number of the P1/2 trials will be followed with P3 trials, the contracts for which will be larger still ($3m-$6m)
- and finally this may lead to the assay / parsortix being used as a companion diagnostic (Cdx) which will deliver significant annual revenue (tens of millions)
So the key message is THESE ASSAY CONTRACTS are critical as they open the gates to the high volume downstream cashflow.
As my brother (who has worked in biotech sales or over 24 years) said when the last contract was announced, "where one large pharma goes the others will quickly follow as nobody wants to be left at a disadvantage".
Just look at the sells this morning...., dribs and drabs...it looks like DHSS money being gambled. Not exactly what it is meant for.
Angle now have one contract with Eisai Inc. of Japan (top 100 Company in Japan) and two contracts with Astrazeneca (Top 100 UK Plc). Doing business with these MASSIVE Companies is only going to lead to more and more contracts with them.......... AND other Plc's IN THE WORLD. The World is a big place and there are thousands of other Companies out that can obviously contact Angle via their WEB site and go from there. The "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample" is going to be transformational for Angle, and they have not YET announced the first customer following the RNS of 4th Jan:-
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
Can't wait!! They are going to be turning customers away IMHO.
All IMHO.
I have been highly critical of Nero’s ‘hype n hope’ strategy, aand its impact on investors and the share price. And until today we have had a trickle of tiny commercial deals that did nothing to assuage my concerns about the commercial case for the company. However, credit where credit due, this morning’s deal is very welcome news, and Newland is to be congratulated ! If he and Brett Swansinger can continue to drive the commercial momentum and sign more 500k deals like this then sentiment may start to swing back in Newland’s direction. Clearly there is a fund raise coming but this time it may be taking place against a more positive commercial background. One swallow doesn’t make a summer, and Newland has disappointed too many times to get carried away, but I cannot deny I feel happier this morning than I have been since the fund raise at 80p
Buying another few chunks this morning - this kind of order may remind folk of Angle's prospects - I just wish we had someone other than AN leading the charge...
Good to lose these stupid traders playing the charts. i just hope MMs will let this go and find s astrong base at 16p.
No fundraise required. Read the rns
Should extend the cash runway by 1 to 2 weeks before the next raise but positive step in the right direction
I hope those that followed TwoGood2die are thanking him this morning....what a plonker.
IMHO all, and I mean ALL Companies that AGL now work with will **ALSO** want this "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample" for cancer treatment studies that involve metastasized cancer. It is obvious. They *******MUST******* WANT THIS imho. HOW ELSE CAN THEY MONITOR THE CANCER????
"BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCER.
Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches to help guide treatment decisions
The new DNA sample-to-answer molecular solution combining CTC and ctDNA analysis is expected to be a driver of product and pharma services sales".
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
These agreements to date are just the start.
Angle simply must be in discussions about the "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample". It will me massive IMHO..............
All IMHO.
I must admit this feels like progress EC…..
TGTD,
You are a silly billy!
Wonder if AZ have registered labs in which they can validate what the hell they wish in the blink of an eye!
You just sit quietly in the corner. Everything will be alright :-)
Only need another £5m+...
It doesn't matter, you evil grouch.